Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cenntro Electric Group

OrganiGram Holdings Inc.

SNDL Inc.

Penny stocks are usually more trouble than they're worth.

4 Penny Stocks Retail Investors Can't Stop Buying

ANN ARBOR, Mich., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that Sean Whelan has been appointed to its Board of Directors to fill the vacancy created by the resignation of Christopher Wolfenberg.

Sean Whelan Appointed to Board of Directors

DarkPulse, Inc.

Farmmi

Why investors are focusing on these 3 Reddit penny stocks right now The post Best Reddit Penny Stocks to Buy? 3 to Know About Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Reddit Penny Stocks to Buy? 3 to Know About Right Now

The launch of the Truforma diagnostic platform didn't go perfectly for Zomedica, but holders of ZOM stock still have reason for optimism. The post If at First Zomedica Doesn't Succeed, It Tries, Tries Again appeared first on InvestorPlace.

If at First Zomedica Doesn't Succeed, It Tries, Tries Again

Zomedica started selling its TRUFORMA vet diagnostic system in March, but ZOM stock won't see upside until supplier assay issues are resolved. The post Is Zomedica Stock Worth the Risk?

Is Zomedica Stock Worth the Risk? Unfortunately It's Complicated

Although ZOM stock banks superficially on millennials' love for pets, brewing economic pressures may undo this catalyst. The post Why Economic Pressure May Build Against Zomedica appeared first on InvestorPlace.

Why Economic Pressure May Build Against Zomedica

Aurora Cannabis

AMC Entertainment

GameStop

Robinhood

Popularity doesn't necessarily translate to profitability on Wall Street.

5 Ultra-Popular Stocks to Avoid Like the Plague in September

Cinedigm

Evofem Biosciences Inc

Globalstar

Moving Image Technologies

China Rapid Finance

Looking for the best industries to find penny stocks in 2021? Check these 3 out The post Penny Stock Investors Are Watching These Hot Industries in September appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stock Investors Are Watching These Hot Industries in September

It's been 3.5 months since Zomedica launched Truforma. Unfortunately, due to its poor execution, ZOM stock continues to suffer.

Zomedica Continues to Execute Poorly

Giving away razors and charging for the blades is often a good idea, but ZOM stock still isn't a good value until it drops closer to 40 cents. The post Zomedica's Business Model Is Good, But It's Still Overpriced appeared first on InvestorPlace.

Zomedica's Business Model Is Good, But It's Still Overpriced

After its post-meme collapse, pet healthcare play ZOM stock is still pricey. Wait for it to inch closer to a more optimal entry point.

The Time to Buy Zomedica Stock May Be Near

Zomedica has an interesting story that could work out. However, the company's inability to execute is raising key concerns about ZOM stock.

Zomedica Needs to Start Delivering Tangible Results

ZOM stock needs to ramp up sales by a significant margin before investors can get excited about investing in it at this time The post Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar

Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now

After months of declining, ZOM stock may have found a floor. The question is if that will hold and whether it makes the beleaguered stock a good buy?

ZOM Stock Is on the Move, but That Doesn't Make It a Good Play Here

Shares of Zomedica Corp. (NYSE: ZOM) are trading higher after the company released earnings. If the stock continues to rally, there's a chance it runs into sellers around the 72-cent level.

Zomedica's Stock Approaches Important Level

Investors appear to be bullish about the stock after a major investment bank disclosed earlier this week that it had bought shares of Zomedica.

Why Zomedica Stock Is Zooming Higher Today

Zomedica (ZOM) stock is soaring higher on Thursday as the stock continues a rally that's been taking place over the last couple of days. The post ZOM Stock: What Investors Are Saying About Meme Stock Favorite Zomedica as Shares Fly appeared first on InvestorPlace.

ZOM Stock: What Investors Are Saying About Meme Stock Favorite Zomedica as Shares Fly

A lack of sales growth and rising expenses could send this struggling stock even lower.

1 Number That Might Send Investors Running From Zomedica's Stock

Today, investors in Zomedica are seeing a lot of green as a recent meme-stock surge takes ZOM stock materially higher. The post ZOM Stock: Can the Latest Meme Stocks Surge Take Zomedica to $1?

ZOM Stock: Can the Latest Meme Stocks Surge Take Zomedica to $1?

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) increased by over 31% during intraday trading. This is why it happened.

ZOM Stock: Over 31% Increase Explanation

So far, it hasn't been easy to stay the course with ZOM stock. Q3 and Q4 developments, however, should lift the shareholders' spirits.

The Second Half of 2021 Should Be Much Easier for Zomedica Investors

There are a few glaring reasons behind the once high-flying stock's decline.

Why Zomedica Stock Has Lost Its Luster

The shares of Zomedica Corp. (NYSE American: ZOM) fell over 10% pre-market. This is why it happened.

Zomedica Shares Fell Over 10% Pre-Market: Why It Happened

TRUFORMA® Instrument Placement Program Implemented to Incentivize Future Assay Sales TRUFORMA® Instrument Placement Program Implemented to Incentivize Future Assay Sales

Zomedica Announces Second Quarter 2021 Financial Results

ZOM stock is trading at a discount, which means this is the perfect time for investors to trade this one for short-term profits. The post Zomedica Is an Excellent Spec Play After Falling appeared first on InvestorPlace.

News for Zomedica Stock (ZOM)